Junyan Xu

ORCID: 0009-0008-3582-847X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Medical Imaging Techniques and Applications
  • Radiomics and Machine Learning in Medical Imaging
  • Colorectal Cancer Surgical Treatments
  • Colorectal Cancer Treatments and Studies
  • Neuroendocrine Tumor Research Advances
  • Ovarian cancer diagnosis and treatment
  • Cancer, Hypoxia, and Metabolism
  • Colorectal and Anal Carcinomas
  • Prostate Cancer Treatment and Research
  • Neuroblastoma Research and Treatments
  • MRI in cancer diagnosis
  • Lung Cancer Research Studies
  • Prostate Cancer Diagnosis and Treatment
  • Advanced X-ray and CT Imaging
  • Bladder and Urothelial Cancer Treatments
  • Advanced Radiotherapy Techniques
  • Breast Lesions and Carcinomas
  • Radiopharmaceutical Chemistry and Applications
  • Genetic factors in colorectal cancer
  • Breast Cancer Treatment Studies
  • Multiple and Secondary Primary Cancers
  • Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Artificial Intelligence in Healthcare
  • Glycosylation and Glycoproteins Research
  • GDF15 and Related Biomarkers

Fudan University Shanghai Cancer Center
2014-2025

Shanghai Medical College of Fudan University
2011-2025

Fudan University
2013-2025

The University of Sydney
2021

Shanghai Jiao Tong University
2021

GTx (United States)
2019

Laboratoire d’Imagerie Biomédicale
2018

Wake Forest University
2004-2013

Cancer Institute (WIA)
2013

Johns Hopkins University
2006

Although endocrine therapy is an effective method to treat estrogen receptor (ER)–positive breast cancer, approximately 30%–40% of all hormone receptor–positive tumors display de novo resistance. The aim our current study was analyze whether <sup>18</sup>F-labeled fluoromisonidazole (1-(2-nitro-1-imidazolyl)-2-hydroxy-3-fluoropropane [<sup>18</sup>F-FMISO]) PET/CT could predict primary resistance hormonal in ER-positive cancer. <b>Methods:</b> Postmenopausal women who had ER-α–positive...

10.2967/jnumed.112.111963 article EN Journal of Nuclear Medicine 2013-02-11

Accumulating epidemiologic and molecular evidence suggest that inflammation is an important component in the etiology of prostate cancer. Macrophage-inhibitory cytokine-1 (MIC-1), a member transforming growth factor beta superfamily, thought to play role by regulating macrophage activity. We examined whether sequence variants MIC-1 gene are associated with risk cancer.The study population, population-based case-control Sweden, consisted 1383 cancer case patients 780 control subjects. From 94...

10.1093/jnci/djh227 article EN JNCI Journal of the National Cancer Institute 2004-08-17

Glycolysis is considered to be the root of cancer development and progression, which involved a multi-step enzymatic reaction. Our study aimed at figuring out glycolysis enzyme participates in colorectal its possible mechanisms.We firstly screened Aldolase B (ALDOB) by performing qRT-PCR arrays glycolysis-related genes five paired liver metastasis primary tissues, further detected ALDOB protein with immunohistochemistry tissue microarray (TMA) consisting 229 samples from stage I-III...

10.1159/000477484 article EN cc-by-nc-nd Cellular Physiology and Biochemistry 2017-01-01

Abstract Background To develop and validate a survival model with clinico-biological features 18 F- FDG PET/CT radiomic via machine learning, for predicting the prognosis from primary tumor of colorectal cancer. Methods A total 196 pathologically confirmed patients cancer (stage I to stage IV) were included. Preoperative clinical factors, serum markers, included recurrence-free analysis. For modeling validation, randomly divided into training (n = 137) validation 59) set, while 78 III...

10.1186/s12967-022-03262-5 article EN cc-by Journal of Translational Medicine 2022-02-02

This study was designed to evaluate the efficacy and toxicities of concomitant boost intensity-modulated radiation therapy (IMRT) along with capecitabine oxaliplatin, followed by a cycle Xelox, in neoadjuvant course for locally advanced rectal cancer. Patients histologically confirmed, newly diagnosed, adenocarcinoma (cT3-T4 and/or cN+) located within 12 cm anal verge were included this study. received IMRT pelvis 50 Gy 5 primary tumor 25 fractions, concurrent oxaliplatin (50 mg/m2 d1...

10.1186/1748-717x-9-70 article EN cc-by Radiation Oncology 2014-03-07

A novel rare mutation, homeobox B13 ( HOXB13 ) G84E, was reported to co-segregate with prostate cancer (PCa) in hereditary PCa families and associate risk unrelated cases controls. In this study, we aim compare the G84E mutation frequency among subjects of different races/ethnicities from various geographic regions world assess its for developing PCa, Reduction by Dutasteride Prostate Cancer Events (REDUCE) trial. All 3508 had initial negative biopsy were biopsied at Year 2 4 detection PCa....

10.1093/carcin/bgt055 article EN Carcinogenesis 2013-02-07

The aim of this prospective, single-arm phase II trial was to confirm the safety and efficacy neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX) for patients with operable locally advanced colon cancer (CC).Patients computed tomography-defined T4 or lymph node-positive CCs were enrolled. After radiological staging, treated at least 2 cycles NAC consisting 130 mg/m2 on d 1, 1,000 twice daily 14 every 3 weeks, followed by surgery, then rest adjuvant chemotherapy....

10.21147/j.issn.1000-9604.2016.06.05 article EN Chinese Journal of Cancer Research 2016-01-01

This study assessed the clinical significance of incidental colorectal 2-fluoro-2-deoxyglucose (FDG) uptake using (18) F-FDG positron emission tomography/computed tomography (PET/CT) scans and evaluated importance colonoscopy when FDG was observed.A prospective designed conducted at a single institution over 2-year period. In patients undergoing PET/CT scans, all with in colorectum were assigned to have biopsy. The value scanning studied by comparison biopsy results.Among 10,978 one or more...

10.1111/j.1463-1318.2011.02727.x article EN Colorectal Disease 2011-08-11

To present the surgical outcomes of advanced epithelial ovarian cancer (AEOC) since implementation a personalized approach and to validate multiple predictive models for R0 resection. Personalized strategies included: 1) Non-invasive model: preoperative clinico-radiological assessment according Suidan criteria with score all individuals. Patients 0-2 were recommended primary debulking surgery (PDS, group A), or otherwise counseled on choices PDS, neoadjuvant chemotherapy (NAC, B) staging...

10.3802/jgo.2018.29.e65 article EN cc-by-nc Journal of Gynecologic Oncology 2018-01-01

ObjectiveTo assess the clinical value of dual tracers Positron emission tomography/computed tomography (PET/CT) 18F-fluoroestradiol (18F-FES) and 18F-fluorodeoxyglucose (18F-FDG) in predicting neoadjuvant chemotherapy response (NAC) breast cancer. MethodsEighteen consecutive patients with newly diagnosed, non-inflammatory, stage II III cancer undergoing NAC were included. Before chemotherapy, they underwent both 18F-FES 18F-FDG PET/CT scans. Surgery was performed after three to six cycles...

10.1371/journal.pone.0078192 article EN cc-by PLoS ONE 2013-10-21

Microsatellite instability (MSI) status is an important hallmark for prognosis prediction and treatment recommendation of colorectal cancer (CRC). To address issues due to the invasiveness clinical preoperative evaluation microsatellite status, we investigated value 18F-FDG PET/CT radiomics with machine learning predicting patients.A total 173 patients that underwent scans before operations were retrospectively analyzed in this study. The each patient was identified as instability-high...

10.3389/fonc.2021.702055 article EN cc-by Frontiers in Oncology 2021-07-22

Purpose To investigate the clinical impact and prognostic value of gallium 68 (

10.1148/rycan.230195 article EN Radiology Imaging Cancer 2024-10-18

Abstract Background Lutetium‐177 DOTA‐TATE peptide receptor radionuclide therapy (PRRT) is an established and effective treatment modality for patients with metastatic neuroendocrine tumors (NETs). Purpose This study aims to predict patient‐absorbed doses from [177Lu]Lu‐DOTA‐TATE PRRT in the liver, kidney lesion by utilizing patient‐specific absorbed pre‐therapeutic [68Ga]Ga‐DOTA‐TATE PET/CT. Methods Before of cycle 1, 11 NETs underwent PET/CT scans at 0.5, 1.0, 2.0 4.0 h after injection...

10.1002/mp.17852 article EN Medical Physics 2025-04-23

Abstract Introduction or hypothesis The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared placebo. However, there is a lack of sufficient retrospective data on surufatinib’s efficacy in treating thymic neuroendocrine tumors (TNETs). This aimed to evaluate the and safety well-differentiated TNETs by conducting single center analysis. Methods We conducted at Fudan University Shanghai Cancer Center, including 102 TNETs. assessed...

10.1093/oncolo/oyaf072 article EN cc-by The Oncologist 2025-05-01

In patients with recurrent or metastatic paragangliomas, 68 Ga-DOTA-NaI3-octreotide PET/CT showed higher sensitivity than 18 F-fluoro-l-3,4-dihydroxyphenylalanine ( F-FDOPA) for detecting bone metastases, and F-FDOPA was more sensitive liver metastases.

10.1148/rycan.240059 article EN Radiology Imaging Cancer 2024-12-06

To investigate the value of whole-body fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for detection metastatic bladder cancer.From December 2006 to August 2010, 60 cancer patients (median age 60.5 years old, range 32-96) underwent whole body tomography. The diagnostic accuracy was assessed by performing both organ-based and patient-based analyses. Identified lesions were further studied biopsy or clinically followed at least 6 months.One hundred...

10.1111/j.1442-2042.2012.02989.x article EN International Journal of Urology 2012-03-27

Abstract Aims Based on the hypothesis that first-line chemoradiation followed by chemotherapy was superior for primary tumor and non-inferior distant lesions compared to alone in synchronous unresectable metastases rectal adenocarcinoma, this study designed assess efficacy safety of strategy. Materials methods Thirty two eligible patients received intensity modulated radiation therapy (45 Gy pelvis a concomitant 10 boost gross tumor), along with concurrent weekly capecitabine oxaliplatin....

10.1186/1748-717x-8-10 article EN cc-by Radiation Oncology 2013-01-07

ATBF1 has been recently identified as a candidate prostate tumor suppressor gene. In addition to more unique mutations, two somatic mutations (shortening of polypyrimidine tract [Poly(T)n] and deletion beginning at codon 3381 (3381del)) were each observed in multiple cancer samples both appear have an impact on gene function expression.We assayed recurrent sequence variants germline DNA from cases controls, examined whether carriers these are increased risk for cancer.We found Poly(T)n...

10.1002/pros.20430 article EN The Prostate 2006-04-25

This study aimed to explore the clinical and prognostic significance of pretreatment positron-emission tomography/computed tomography (PET/CT) parameters, especially 2-deoxy-2-(F)fluoro-D-glucose-based heterogeneity, in high-grade serous ovarian cancer (HGSC).We retrospectively investigated 56 patients with HGSC who underwent PET/CT before primary surgery at our hospital between January 2010 June 2015. None these received neoadjuvant chemotherapy. including maximum mean standardized uptake...

10.1097/mnm.0000000000000861 article EN Nuclear Medicine Communications 2018-05-17

Objective Our purpose is to investigate whether the tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine would be influenced when were treated long-acting octreotide. Methods Sixty G2 who underwent single-photon emission computed tomography/computed tomography imaging retrospectively analyzed. The ratios target/muscle normal organs and tumors compared between (n = 30) without octreotide treatment 30). In addition, group was divided into two subgroups based on time intervals more...

10.1097/mnm.0000000000001075 article EN Nuclear Medicine Communications 2019-07-31
Coming Soon ...